Only nine participants with hepatic steatosis were included in the study to allow for inclusion of participants with other dyslipidemias, and further investigations required to evaluate the effect of ARO-ANG3 on liver fat content are included in ongoing phase 2b clinical trials. Here, CYP19A1 is linked to metabolic syndrome.